ストックスクリーナーアプリを入手
2.44
6.09%
0.14
前日終値:
$2.30
開ける：
$2.34
24時間の取引高:
593.96K
Relative Volume:
0.56
時価総額：
$224.19M
収益：
-
当期純損益:
$-36.12M
株価収益率:
-6.3476
EPS:
-0.3844
ネットキャッシュフロー:
$-28.42M
1週間 パフォーマンス:
-2.79%
1か月 パフォーマンス:
-10.29%
6か月 パフォーマンス:
+115.93%
1年 パフォーマンス:
+190.93%
1日の値動き範囲:
$2.31
$2.45
1週間の範囲:
$2.195
$2.51
52週間の値動き範囲:
$0.49
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
名前
Context Therapeutics Inc
セクター
電話
267-225-7416
住所
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
2.44 | 211.32M | 0 | -36.12M | -28.42M | -0.3844 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | Guggenheim | Buy |
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-11-25 | 開始されました | D. Boral Capital | Buy |
| 2024-05-16 | 開始されました | Piper Sandler | Overweight |
Context Therapeutics Inc (CNTX) 最新ニュース
Context Therapeutics settles governance lawsuit with mootness fee - TipRanks
Context Therapeutics (NASDAQ: CNTX) ends charter suit with $850K mootness fee - Stock Titan
H.C. Wainwright Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Context Therapeutics (CNTX) to Release Quarterly Earnings on Wednesday - MarketBeat
[ARS] Context Therapeutics Inc. SEC Filing - Stock Titan
Context Therapeutics (NASDAQ: CNTX) plans vote on board slate and 300M-share authorization - Stock Titan
Positive Signs As Multiple Insiders Buy Context Therapeutics Stock - Yahoo Finance
Context Therapeutics (CNTX) price target increased by 13.33% to 5.78 - MSN
Is Context Therapeutics (CNTX) stock a good candidate for diversification | Q4 2025: EPS Misses EstimatesMarket Risk - Xã Thanh Hà
CNTX (Context Therapeutics Inc.) shares rise 6.11 percent even as Q4 2025 EPS lands below consensus analyst estimates.Trending Volume Leaders - Cổng thông tin điện tử tỉnh Tây Ninh
Is Context Therapeutics (CNTX) stock forming lower lows | Q4 2025: EPS Misses EstimatesPayout Ratio - Xã Vĩnh Công
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Piper Sandler Reaffirms Their Buy Rating on Context Therapeutics (CNTX) - The Globe and Mail
Piper Sandler Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Context Therapeutics (CNTX) seeks 100M-share charter increase ahead of June meeting - Stock Titan
Targets Report: Can Context Therapeutics Inc maintain sales growth2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Rally Mode: What makes Context Therapeutics Inc stock attractive todayWeekly Trend Recap & Stock Market Timing Techniques - baoquankhu1.vn
Is Context Therapeutics Inc likely to announce a buybackMarket Activity Report & Safe Entry Zone Identification - baoquankhu1.vn
History Review: What is Context Therapeutics Incs 5 year growth outlookTrade Analysis Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CNTX Earnings History & Surprises | EPS & Revenue Results | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Investment Report: Will Context Therapeutics Inc stock go up in YEAR2026 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Neogen names Jennifer Evans Stacey as chief legal officer - Investing.com
Food safety company Neogen taps biotech lawyer for legal, compliance post - Stock Titan
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - MSN
Breakouts Watch: How does Context Therapeutics Inc compare to its peers2026 Earnings Surprises & Growth Focused Entry Point Reports - baoquankhu1.vn
JonesTrading Remains a Buy on Context Therapeutics (CNTX) - The Globe and Mail
Buyout Rumor: Is Context Therapeutics Inc stock risky to hold now2026 Gainers & Long-Term Capital Growth Strategies - baoquankhu1.vn
JonesTrading Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Context Therapeutics Gains FDA Fast Track for CTIM-76 - The Globe and Mail
Published on: 2026-04-03 00:59:30 - baoquankhu1.vn
Context Therapeutics Shares Gain on FDA Fast Track Designation for Ovarian Cancer Drug - marketscreener.com
Context Therapeutics wins FDA fast-track status (CNTX:NASDAQ) - Seeking Alpha
Context Therapeutics' CTIM-76 Wins FDA Fast Track; Phase 1a Interim Data Due June 2026 - TradingView
FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan
Context Therapeutics Receives FDA Fast Track Designation for CTIM-76 in Platinum-Resistant Ovarian Cancer - Quiver Quantitative
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy - The Manila Times
Context Therapeutics Announces CTIM-76 Receives FDA Fast - GlobeNewswire
S P Trends: Can Context Therapeutics Inc maintain sales growth2026 Sector Moves & AI Based Trade Execution Alerts - baoquankhu1.vn
Support Test: Will Context Therapeutics Inc stock go up in YEARLayoff News & Fast Entry Momentum Alerts - baoquankhu1.vn
Context Therapeutics (NASDAQ:CNTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Q1 EPS Forecast for Context Therapeutics Lowered by Analyst - MarketBeat
Gains Recap: What makes Context Therapeutics Inc stock attractive todayPortfolio Value Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Insider Sell: Is Context Therapeutics Inc stock risky to hold now2026 Historical Comparison & Real-Time Volume Trigger Notifications - baoquankhu1.vn
HC Wainwright Brokers Reduce Earnings Estimates for CNTX - MarketBeat
Context Therapeutics (NASDAQ:CNTX) and Clearmind Medicine (NASDAQ:CMND) Head-To-Head Contrast - Defense World
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Context Therapeutics (NASDAQ:CNTX) Given Buy Rating at D. Boral Capital - Defense World
Context Therapeutics' (CNTX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Context Therapeutics (NASDAQ:CNTX) Receives Buy Rating from Guggenheim - MarketBeat
Context Therapeutics Inc (CNTX) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):